Corient Private Wealth
PRME icon

Corient Private Wealth’s Prime Medicine PRME Stock Holding History

Corient Private Wealth’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Sell
39,078
-2,143
-5% -$7.12K ﹤0.01% 2873
2026
Q1 		$8.64K Buy
41,221
+2,444
+6% +$9.3K ﹤0.01% 2804
2025
Q4 		$135K Hold
38,777
– – ﹤0.01% 2495
2025
Q3 		$215K Buy
+38,777
New +$158K ﹤0.01% 2315

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Corient Private Wealth's PRME Position: Q2 2026 in Review

Corient Private Wealth reduced its Prime Medicine (PRME) stake by 5.2% in Q2 2026, selling an estimated $7.12K and leaving 39,078 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

Corient Private Wealth first reported a position in PRME in Q3 2025 and has held it in 4 quarters since. The position peaked at $215K in Q3 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Corient Private Wealth held 39,078 shares of Prime Medicine worth $144K as of Q2 2026.
  • Corient Private Wealth sold 2,143 Prime Medicine shares in Q2 2026, an estimated $7.12K.
  • Prime Medicine made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2873 holding.
  • Corient Private Wealth first reported a position in Prime Medicine in Q3 2025 and has held it in 4 quarters since.
  • Corient Private Wealth's Prime Medicine position peaked at $215K in Q3 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.